Skip to main content
SpringerLink
Log in

Deferasirox: Oral, once daily iron chelator — an expert opinion

  • Special Article
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Iron overload is a serious and potentially fatal condition that results from multiple blood transfusions required over a long period of time to treat certain types of anemias such as, that caused by β-thalassemia, sickle cell disease and myelodysplastic syndrome. Deferoxamine, which has been used since four decades as an iron chelator has limited efficacy due to its demanding therapeutic regimen, leading to poor compliance. Deferasirox, once daily oral iron chelator provides an effective alternative to Deferoxamine in the treatment of transfusional hemosiderosis. In this review, the role of Deferasirox as an ideal iron chelator has been discussed. Pubmed searches on Deferasirox were carried out for the same. Several studies demonstrated the safety and efficacy of Deferasirox in reducing iron burden in iron-overloaded patients with β-thalassemia, sickle cell anemia and myelodysplastic anemia. Thus, convenient, effective and tolerable chelation therapy with oral Deferasirox is likely to be a significant development in the treatment of transfusional iron overload, due to its ability to provide constant chelation coverage and the potential to improve compliance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Porter JB. Practical management of iron overload. Br J Haematol 2001; 115: 239–252.

    Article  CAS  PubMed  Google Scholar 

  2. Taher A. Iron overload in thalassemia and sickle cell disease. Semin Hematol 2005; 42: S5–S9.

    Article  CAS  PubMed  Google Scholar 

  3. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739–761.

    CAS  PubMed  Google Scholar 

  4. Thakerngpol K, Fucharoen S, Boonyaphipat P et al. Liver injury due to iron overload in thalassemia: histopathologic and ultrastructural studies. Biometals 1996; 9: 177–183.

    Article  CAS  PubMed  Google Scholar 

  5. Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol 2001; 38: 57–62.

    Article  CAS  PubMed  Google Scholar 

  6. Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, Deferoxamine, ICL670, GT56-252, L1NAll and starch Deferoxamine polymers. Hemoglobin 2006; 30: 329–347.

    Article  CAS  PubMed  Google Scholar 

  7. Barton JC. Deferasirox Novartis. Curr Opin Investig Drugs 2005; 6: 327–335.

    CAS  PubMed  Google Scholar 

  8. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001: 47–61.

  9. Porter JB. Deferasirox: An effective once-daily orally active iron chelator. Drugs Today (Barc) 2006; 42: 623–637.

    Article  CAS  Google Scholar 

  10. Nick H, Acklin P, Lattmann R et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 2003; 10: 1065–1076.

    Article  CAS  PubMed  Google Scholar 

  11. Stumpf JL. Deferasirox. Am J Health Syst Pharm 2007; 64: 606–616.

    Article  CAS  PubMed  Google Scholar 

  12. Vanorden HE, Hagemann TM. Deferasirox—an oral agent for chronic iron overload. Ann Pharmacother 2006; 40: 1110–1117.

    Article  CAS  PubMed  Google Scholar 

  13. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005; 106: 3242–3250.

    Article  CAS  PubMed  Google Scholar 

  14. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 2001; 97: 1115–1122.

    Article  CAS  PubMed  Google Scholar 

  15. Nick H, Wong A, Acklin P et al. ICL670A: preclinical profile. Adv Exp Med Biol 2002; 509: 185–203.

    CAS  PubMed  Google Scholar 

  16. Taher A, El-Beshlawy A, Elalfy MS et al. Efficacy and safety of Deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study. Eur J Haematol 2009; 82:458–465.

    Article  CAS  PubMed  Google Scholar 

  17. Wood JC, Otto-Duessel M, Gonzalez I et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res 2006; 148: 272–280.

    Article  CAS  PubMed  Google Scholar 

  18. Neufeld EJ. Oral chelators Deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006; 107: 3436–3441.

    Article  CAS  PubMed  Google Scholar 

  19. Pathare A, Taher A, Daar S. Deferasirox (Exjade(R)) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major. Ann Hematol 2009 Oct 2. [Epub ahead of print]

  20. Stumpf JL. Deferasirox. Am J Health Syst Pharm 2007; 64: 606–616.

    Article  CAS  PubMed  Google Scholar 

  21. Cappellini MD. Long-term efficacy and safety of Deferasirox. Blood Rev 2008; 22: S35–S41.

    Article  CAS  PubMed  Google Scholar 

  22. Nisbet-Brown E, Olivieri NF, Giardina PJ et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597–1602.

    Article  CAS  PubMed  Google Scholar 

  23. Piga A, Galanello R, Forni GL et al. Randomized phase II trial of Deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to Deferoxamine in Thalassemia patients with transfusional iron overload. Haematologica 2006; 91:873–880.

    CAS  PubMed  Google Scholar 

  24. Vichinsky E, Onyekwere O, Porter J et al. Deferasirox in Sickle Cell Investigators. A randomised comparison of Deferasirox versus Deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136: 501–508.

    Article  CAS  PubMed  Google Scholar 

  25. Porter J, Galanello R, Saglio G et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to Deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008; 80:168–176.

    CAS  PubMed  Google Scholar 

  26. Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing iron overload in patients with myelodysplastic syndromes with oral Deferasirox therapy. Oncologist 2009; 14: 489–496. Epub 2009 Apr 13.

    Article  CAS  PubMed  Google Scholar 

  27. Cappellini MD, Taher A. Long-term experience with Deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother 2008; 9: 2391–2402.

    Article  CAS  PubMed  Google Scholar 

  28. Yang LP, Keam SJ, Keating GM. Deferasirox: a review of its use in the management of transfusional chronic iron overload. Drugs 2007; 67: 2211–2230.

    Article  CAS  PubMed  Google Scholar 

  29. Agarwal MB. Exjade (ICL 670): A new oral iron chelator. J Assoc Physicians India 2006; 54: 214–217.

    CAS  PubMed  Google Scholar 

  30. Cappellini MD, Pattoneri P. Oral iron chelators. Annu Rev Med 2009;60: 25–38.

    Article  CAS  PubMed  Google Scholar 

  31. Taher A, Cappellini MD, Vichinsky E et al. Efficacy and safety of Deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009; 147: 752–759.

    Article  CAS  PubMed  Google Scholar 

  32. Agarwal MB, Rathi SS, Agarwal UM et al. High-dose (>30 mg/k/d) Deferasirox (Asunra, Desirox) therapy is effective and safe in heavily iron loaded patients — An Indian study. Presented at The Annual Conference of Mumbai Haematology Group, Mumbai, March 2009

  33. Exjade. Prescribing Information. April 2009

  34. Taher A, Cappellini MD. Update on the use of Deferasirox in the management of iron overload. Ther Clin Risk Manag 2009; 5: 857–868.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bombay Hospital Institute of Medical Sciences, Marine Lines, Mumbai, India

    M.B. Agarwal

  2. Hematology Centre, Ghamat Lodge, Above ING Vaiysha Bank, 2nd Floor, 804-A, Dr. B. Ambedkar Road, Dadar TT, Mumbai, 400014, India

    M.B. Agarwal

Authors
  1. M.B. Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M.B. Agarwal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agarwal, M. Deferasirox: Oral, once daily iron chelator — an expert opinion. Indian J Pediatr 77, 185–191 (2010). https://doi.org/10.1007/s12098-010-0030-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-010-0030-4

Key words

Search

Navigation